2/ For decades, doctors have had to compromise when monitoring the brain - using risky, invasive, expensive procedures that involve drilling into the skull, or inaccurate non-invasive tools that can lead to poor treatment decisions.

3/ To take just one example of why this matters, 3m patients suffer traumatic brain injuries (TBIs) every year in the US alone, but only 5% receive an intracranial pressure test, because it requires drilling a hole in the skull and carries a 15% complication rate.

4/ The rest are treated with limited information, leading to worse data, worse outcomes and higher costs.

5/ London-based CoMind is changing that. Its optical neuromonitoring platform can measure three core brain health indicators - cerebral blood flow, autoregulation and intracranial pressure non-invasively - something that has never been done before.

6/ It’s a breakthrough that could help tens of millions of patients worldwide and redefine how we understand and treat the brain.

7/ The company is led by a true outlier of a young founder, @jamesdacombe. He started programming when he was 13 and founded CoMind when he was just 17.

@jamesdacombe 8/ His work ethic and rapid learning rate have led him to build a working product and take it through two successful clinical research studies, with the help of a stellar leadership team of medical and industry veterans from e.g. Medtronics, Tufts & UCL.

@jamesdacombe 9/ This is only the beginning. CoMind plans to expand its product portfolio to measure additional physiological parameters and develop CoVision, an AI platform that transforms sensor data into predictive insights, identifying complications early and personalising treatment.

@jamesdacombe 10/ The company aims to gain regulatory approval within two years, unlocking access to the huge ICU market in the US. This first sensor can revolutionise TBI monitoring, and a second device is already in development to measure more parameters and treat more brain conditions.

@jamesdacombe 11/ This technology has the potential to dramatically improve how we monitor our brains, giving doctors better information and more choices for treating patients, while building out a whole new market by providing a far more affordable and safe alternative to existing solutions.

@jamesdacombe 12/ Read more about why we invested in CoMind here:

@jamesdacombe 13/ And coverage by the @FT's @tim here:

@taavet @pluralplatform @CoMind_ Congrats team!

@taavet @pluralplatform @CoMind_ Awesome. Congratulations!